Bioequivalence of IR vs MR tablet [Design Issues]

posted by heritage – India, 2018-05-05 04:25 (935 d 11:48 ago) – Posting: # 18755
Views: 2,775

One drug has been approved as IR tablet given 100 mg bid (total dose 200 mg). We want to make one ER formulation of 230 mg which can be given once daily. I need help in following issues

1. What should be the design?
2. Which PK parameter I should be looking at?
3. Should I do fasting or fed study?
4. Should I targeting BE in Cmax or AUC?

Please give me some reading material or link to any post wherein this had been already discussed

Thanks in advance


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

Activity
 Admin contact
21,210 posts in 4,426 threads, 1,481 registered users;
online 14 (0 registered, 14 guests [including 13 identified bots]).
Forum time: Wednesday 16:14 UTC (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5